1.	ABT-888 and Cyclophosphamide With Versus Without Doxorubicin in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000600234, P30CA072720, CINJ-050803, 050803, 7998, NCT00740805
2.	Phase I/II Study of ABT-888 and Topotecan Hydrochloride in Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0861, MC0861, 8329, NCT01012817
3.	Phase I/II Randomized Study of Veliparib and Temozolomide in Patients With Recurrent Glioblastoma (Phase I closed and Phase II opened on 3/6/12) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0929, RTOG-0929, NCT01026493
4.	Phase I/II Study of Paclitaxel, Cisplatin, and Veliparib in Patients With Advanced, Persistent, or Recurrent Carcinoma of the Cervix Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0076HH, GOG-0076HH, NCT01281852
5.	Phase I/II Study of Veliparib, Bendamustine Hydrochloride, and Rituximab in Patients With Advanced Recurrent Lymphoma, Multiple Myeloma, or Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-10174, 10-174, 8818, NCT01326702
6.	Phase I/II Randomized Study of Cyclophosphamide With Versus Without Veliparib in Patients With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive and HER2/neu-Negative Locally Advanced or Metastatic Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: AECM-11-02-068, 11-02-068, 8853, NCT01351909
7.	Phase I/II Partially Randomized Study of Veliparib With Versus Without Chemoradiotherapy Comprising Carboplatin and Paclitaxel in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CHNMC-PHII-111, PHII-111, 8811, NCT01386385
8.	Phase I/II Study of Veliparib, Radiotherapy, and Temozolomide in Children With Newly Diagnosed Diffuse Pontine Gliomas Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: NCI Protocol IDs: PBTC-033, PBTC-033, NCT01514201
9.	Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Veli-BRCA, NCT01472783
10.	ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LCCC 2009-608, NCT01489865
11.	Phase I/II Randomized Study of Cisplatin and Etoposide With Versus Without Veliparib in Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E2511, E2511, NCT01642251
12.	I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 097517, NCT01042379
13.	A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-170, NCT01051596
14.	Phase II Study of Single-Agent Veliparib Followed by Post-Progression Veliparib and Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CHNMC-PHII-96, PHII-96, 8264, NCT01149083
15.	ABT-888 and Temozolomide for Liver Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-268, NCT01205828
16.	Phase II Study of Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Patients With Persistent or Recurrent Squamous Cell or Non-Squamous Cell Carcinoma of the Cervix Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0127W, GOG-0127W_2010-12-14, NCT01266447
17.	The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer. Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M12-895, 2011-002913-12, NCT01506609
18.	A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M10-898, 2011-003427-36, NCT01560104
19.	Phase II Randomized Study of Abiraterone Acetate With or Without Veliparib in Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-IL057, IL057, 9012, NCT01576172
20.	Phase II Randomized Study of Gemcitabine Hydrochloride and Cisplatin With Versus Without Veliparib Versus Veliparib Alone in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Pancreas and Known BRCA and/or PALB2 Mutation Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-12-045, 12-045, 8993, NCT01585805
21.	Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01130, U01CA070095, IRB #12-021, NCT01638546
22.	A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M10-897, 2011-003618-18, NCT01657799
23.	Phase I Study of Veliparib, Carboplatin, and Paclitaxel in Patients With Advanced Solid Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: PCI-07-015, 07-015, 7967, NCT00535119
24.	ABT-888 and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: J0783 CDR0000579626, U01CA070095, P30CA006973, JHOC-J0783, J0783, 7968, NCT00588991
25.	A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M10-128, NCT00649207